Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New tactic: Warning letters to health care providers

This article was originally published in The Silver Sheet

Executive Summary

On Oct. 27, FDA sent warning letters to 17 ambulatory surgical centers that perform laser-assisted in situ keratomileusis (LASIK) procedures, citing the facilities for failure to develop, maintain and implement written Medical Device Reporting (MDR) procedures. (See "1Warning Letters") CDRH has also stepped up communications with health care facilities and professional societies to clarify the agency's requirements for MDR reporting. CDRH Office of Compliance Director Tim Ulatowski says it's "vitally important" that user facilities, and not just device manufacturers, comply with MDR regulations. Under the regulation, hospitals and other user facilities must submit a report to both FDA and the manufacturer when a device may have caused or contributed to a death. When it may have caused or contributed to a serious injury, the facility generally only needs to tell the manufacturer. "If the manufacturers aren't getting the reports and FDA is not getting the reports from user facilities when necessary, then the whole system breaks down, or is at least in jeopardy," Ulatowski says. "We need to be receiving these reports so we can properly assess in a post-market period how these devices that are involved in LASIK procedures are performing.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel